CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (44,444,888)	$ (42,985,123)
Adjustment to reconcile to net loss to net cash used in operating activities:
Depreciation and amortization expense	248,628	269,691
Reduction in carrying amount of right-of-use assets	255,660	247,165
Intangible asset amortization	21,950	21,950
Stock-based compensation expense	4,673,290	4,776,623
Net accretion of discount on marketable securities	0	(203,491)
Loss on disposal of fixed assets	0	1,315
(Increase) decrease in:
Prepaid expenses and other current assets	1,904,097	(1,183,785)
Other assets	802,848	(261,337)
Increase (decrease) in:
Accounts payable	(474,214)	(168,884)
Accrued expenses	1,908,736	(581,135)
Lease liabilities	(246,528)	(221,934)
Other liabilities	(153,576)	(200,113)
Net cash used in operating activities	(35,503,997)	(40,489,058)
Cash flows from investing activities:
Purchases of property and equipment	(18,316)	(75,519)
Purchases of marketable securities	0	(5,410,170)
Maturities of marketable securities	0	26,430,000
Net cash (used in) provided by investing activities	(18,316)	20,944,311
Cash flows from financing activities:
Proceeds from exercise of stock options	138,700	732,458
Proceeds from issuance of common stock under employee stock purchase plan	421,910	374,652
Proceeds from issuance of common stock through private placement with Aventis Inc	25,000,000	0
Payment of offering and placement costs	(3,138,911)	0
Net cash provided by financing activities	226,940,670	5,344,507
Net increase (decrease) in cash and cash equivalents	191,418,357	(14,200,240)
Cash and cash equivalents at beginning of period	36,144,720	59,405,817
Cash and cash equivalents at end of period	227,563,077	45,205,577
Supplemental disclosures of noncash information:
Offering and placement costs included in accounts payable/accrued expenses	845,933	0
At-the-market offering
Cash flows from financing activities:
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs	15,020,046	4,237,397
Warrant
Cash flows from financing activities:
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs	24,998,919	0
Public Offering
Cash flows from financing activities:
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs	164,500,006	$ 0
Private Placement
Cash flows from financing activities:
Payment of offering and placement costs	$ (1,600,000)

Offering Costs Included In Accounts Payable And Accrued Expenses

No definition available.

Name:	imrx_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
Namespace Prefix:	imrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.